The partners of Capital IP have successfully acquired over $300M of these “legacy assets”, which frequently are off-patent branded generics, from large pharmaceutical companies. We have extensive experience partnering with entrepreneurial teams – typically industry executives with a deep knowledge of specific products – to acquire and manage these brands in ways that maintain and strengthen their value over time. Our focus is on products in stable markets that offer highly predictable cash flows.

Our transactions enable our counterparties to invest in higher return activities such as acquiring new technologies, financing development projects. and meeting additional working capital needs.